Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Old Meets New: Hydroxyurea Synergistically Enhances the Antileukemic Activity of Gilteritinibagainst FLT3-ITD AML

Nibal Eid, Jianlei Zhao, Jenna Thibodeau, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H Dzinic, Kathryn H White, Steven Buck, Jeffrey W. Taub, Yubin Ge

Blood (2024) 144 (Supplement 1): 5805.

https://doi.org/10.1182/blood-2024-207855

Published: 2024

Journal Articles

Loss of Cystathionine-β-Synthase Activity Results in Increased Oxidative Phosphorylation and Cytarabine Resistance in Myeloid Leukemia Associated with Down Syndrome

Jenna Thibodeau, Jianlei Zhao, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H Dzinic, Kathryn H White, Maik Hüttemann, Tasnim Arroum, Lucynda Pham, Austin C. Boucher, John D. Crispino, Jeffrey W. Taub, Yubin Ge

Blood (2024) 144 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2024-203961

Published: 2024

Journal Articles

Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome

Austin C. Boucher, Wojciech Rosikiewicz, Ricky Tirtakusuma, Anitria Cotton, Madeline Niederkorn, Elvin Wagenblast, Paul G. Thomas, Yubin Ge, Jeffrey W. Taub, Jan-Henning Klusmann, John D. Crispino

Blood (2024) 144 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2024-210782

Published: 2024

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis

Katie Hege Hurrish, Yongwei Su, Sandra Wiley, Zhanjun Hou, Jenna Carter, Hasini Kalpage, Maik Hüttemann, Holly Edwards, Lisa Polin, Jing Li, Jay Yang, Larry Matherly, Jeffrey W. Taub, Yubin Ge

Blood (2021) 138 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2021-147004

Published: 2021

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Tristan Knight, MD, Xinan Qiao, BS, Jun Ma, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Kathryn White, Hai Lin, MD, Yue Wang, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2019) 134 (Supplement_1): 1262.

https://doi.org/10.1182/blood-2019-123793

Published: 2019

Journal Articles

Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome

Austin L. Brown, Adam J. de Smith, Vincent U. Gant, Wenjian Yang, Michael E. Scheurer, Kyle M. Walsh, Jonathan M. Chernus, Noah A. Kallsen, Shanna A. Peyton, Gareth E. Davies, Erik A. Ehli, Naomi Winick, Nyla A. Heerema, Andrew J. Carroll, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Elizabeth A. Raetz, Eleanor Feingold, Meenakshi Devidas, Lisa F. Barcellos, Helen M. Hansen, Libby Morimoto, Alice Y. Kang, Ivan Smirnov, Jasmine Healy, Caroline Laverdière, Daniel Sinnett, Jeffrey W. Taub, Jillian M. Birch, Pamela Thompson, Logan G. Spector, Maria S. Pombo-de-Oliveira, Andrew T. DeWan, Charles G. Mullighan, Stephen P. Hunger, Ching-Hon Pui, Mignon L. Loh, Michael E. Zwick, Catherine Metayer, Xiaomei Ma, Beth A. Mueller, Stephanie L. Sherman, Joseph L. Wiemels, Mary V. Relling, Jun J. Yang, Philip J. Lupo, Karen R. Rabin

Blood (2019) 134 (15): 1227–1237.

https://doi.org/10.1182/blood.2018890764

Published: 2019

Includes: Supplemental data

Journal Articles

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Yongwei Su, Xinyu Li, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Katie Hege, Yu Fukuda, John D. Schuetz, PhD, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 3936.

https://doi.org/10.1182/blood-2018-99-116997

Published: 2018

Journal Articles

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Blood (2018) 132 (Supplement 1): 543.

https://doi.org/10.1182/blood-2018-99-116661

Published: 2018

Journal Articles

Inhibition of ATR Potentiates Acute Myeloid Leukemia Cells to the RNA Pol I Transcription Inhibitor CX-5461

Margaret Shatara, MD, Tingting Wang, Xinyu Li, Holly Edwards, BS, Jeffrey W. Taub, MD, Hai Lin, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 5224.

https://doi.org/10.1182/blood-2018-99-113937

Published: 2018

Journal Articles

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Daniel A Luedtke, BS, Yongwei Su, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Hai Lin, MD, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 1361.

https://doi.org/10.1182/blood-2018-99-118372

Published: 2018

Journal Articles

Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib

Tristan Knight, MD, Xinan Qiao, BS, Holly Edwards, BS, Hai Lin, MD, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2018-99-111177

Published: 2018

Journal Articles

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Yongwei Su, Xinyu Li, Jianyun Zhao, Jun Ma, Shuang Liu, Holly Edwards, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 1255.

https://doi.org/10.1182/blood.V130.Suppl_1.1255.1255

Published: 2017

Journal Articles

Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia

Daniel A Luedtke, BS, Yongwei Su, Holly Edwards, Hai Lin, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3819.

https://doi.org/10.1182/blood.V130.Suppl_1.3819.3819

Published: 2017

Journal Articles

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Yongwei Su, Xinyu Li, Holly Edwards, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3822.

https://doi.org/10.1182/blood.V130.Suppl_1.3822.3822

Published: 2017

Journal Articles

A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemic Pathogenesis

Andrew Volk, PhD, Kaiwei Liang, PhD, Jianyun Zhao, Xinyu Li, Marinka Bulic, Stacy Marshall, Jeffrey W. Taub, MD, Yubin Ge, PhD, Sebastien Malinge, PhD, Elizabeth Bartom, PhD, Ali Shilatifard, PhD, John D. Crispino, PhD

Blood (2017) 130 (Supplement 1): 245.

https://doi.org/10.1182/blood.V130.Suppl_1.245.245

Published: 2017

Journal Articles

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Jeffrey W. Taub, Jason N. Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David Head, Susana Raimondi, Betsy Hirsch, Yubin Ge, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis

Blood (2017) 129 (25): 3304–3313.

https://doi.org/10.1182/blood-2017-01-764324

Published: 2017

Includes: Supplemental data

Journal Articles

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Xinyu Li, Jun Ma, Yongwei Su, Jianyun Zhao, Holly Edwards, Yue Wang, Jay Yang, MD, Jeffrey W Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2016) 128 (22): 1571.

https://doi.org/10.1182/blood.V128.22.1571.1571

Published: 2016

Journal Articles

Learning Not to Judge a Book By Its Cover: A Case Series of Malignancy Masquerading As Common Presentations of Sickle Cell Disease

Ahmar Urooj Zaidi, MD, Lo'Rell Martin, DO, Michael U Callaghan, MD, Sharada A. Sarnaik, MD, Jeffrey W Taub, MD

Blood (2016) 128 (22): 4872.

https://doi.org/10.1182/blood.V128.22.4872.4872

Published: 2016

NARROW

Old Meets New: Hydroxyurea Synergistically Enhances the Antileukemic Activity of Gilteritinibagainst FLT3-ITD AML

Loss of Cystathionine-β-Synthase Activity Results in Increased Oxidative Phosphorylation and Cytarabine Resistance in Myeloid Leukemia Associated with Down Syndrome

Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Inhibition of ATR Potentiates Acute Myeloid Leukemia Cells to the RNA Pol I Transcription Inhibitor CX-5461

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemic Pathogenesis

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Learning Not to Judge a Book By Its Cover: A Case Series of Malignancy Masquerading As Common Presentations of Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only